Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment

Mondal, Amal Chandra; Fatima, Mahino

doi:10.1080/00207454.2018.1527328

Cited by 93 publications

(53 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, RAB7A was demonstrated to modulate endoplasmic reticulum stress [35], which is associated with mood disorders [36,37]. Other functions of RAB7A include growth-factormediated cell signalling and lipid metabolism [38], which are also proposed mechanisms involved in the pathophysiology of mood disorders [39,40]. Further studies focusing on the association between RAB7A and the different manifestations of mood disorders based on these functions are needed.…”

Section: Discussionmentioning

confidence: 99%

Comparison of serum protein profiles between major depressive disorder and bipolar disorder

et al. 2020

View full text Add to dashboard Cite

Background: Major depressive disorder and bipolar disorder are prevalent and debilitating psychiatric disorders that are difficult to distinguish, as their diagnosis is based on behavioural observations and subjective symptoms. Quantitative protein profile analysis might help to objectively distinguish between these disorders and increase our understanding of their pathophysiology. Thus, this study was conducted to compare the peripheral protein profiles between the two disorders. Methods: Serum samples were collected from 18 subjects with major depressive disorder and 15 subjects with bipolar disorder. After depleting abundant proteins, liquid chromatography-tandem mass spectrometry (LC-MS/MS) and label-free quantification were performed. Data-dependent acquisition data were statistically analysed from the samples of 15 subjects with major depressive disorder and 10 subjects with bipolar disorder who were psychotropic drug-free. Two-sided t-tests were performed for pairwise comparisons of proteomes to detect differentially-expressed proteins (DEPs). Ingenuity Pathway Analysis of canonical pathways, disease and functions, and protein networks based on these DEPs was further conducted. Results: Fourteen DEPs were significant between subjects with major depressive disorder and those with bipolar disorder. Ras-related protein Rab-7a (t = 5.975, p = 4.3 × 10 − 6) and Rho-associated protein kinase 2 (t = 4.782, p = 8.0 × 10 − 5) were significantly overexpressed in subjects with major depressive disorder and Exportin-7 (t =-4.520, p = 1.5 × 10 − 4) was significantly overexpressed in subjects with bipolar disorder after considering multiple comparisons. Bioinformatics analysis showed that cellular functions and inflammation/immune pathways were significantly different. Conclusions: Ras-related protein Rab-7a, Rho-associated protein kinase 2, and Exportin-7 were identified as potential peripheral protein candidates to distinguish major depressive disorder and bipolar disorder. Further large sample studies with longitudinal designs and validation processes are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of serum protein profiles between major depressive disorder and bipolar disorder

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Over the last years, there has been a great interest in peripheral BDNF measures in relation to psychiatric illness. It has been studied as biomarker reflecting these disorders [ 188 , 189 ]. However, there is no evidence that serum BDNF is related to brain BDNF and neuroplasticity.…”

Section: Neuroplasticity In Mdd: the Effects Of Antidepressant Thementioning

confidence: 99%

Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer

Colucci-D’Amato

Speranza

Volpicelli

2020

IJMS

464

249

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) is one of the most distributed and extensively studied neurotrophins in the mammalian brain. BDNF signals through the tropomycin receptor kinase B (TrkB) and the low affinity p75 neurotrophin receptor (p75NTR). BDNF plays an important role in proper growth, development, and plasticity of glutamatergic and GABAergic synapses and through modulation of neuronal differentiation, it influences serotonergic and dopaminergic neurotransmission. BDNF acts as paracrine and autocrine factor, on both pre-synaptic and post-synaptic target sites. It is crucial in the transformation of synaptic activity into long-term synaptic memories. BDNF is considered an instructive mediator of functional and structural plasticity in the central nervous system (CNS), influencing dendritic spines and, at least in the hippocampus, the adult neurogenesis. Changes in the rate of adult neurogenesis and in spine density can influence several forms of learning and memory and can contribute to depression-like behaviors. The possible roles of BDNF in neuronal plasticity highlighted in this review focus on the effect of antidepressant therapies on BDNF-mediated plasticity. Moreover, we will review data that illustrate the role of BDNF as a potent protective factor that is able to confer protection against neurodegeneration, in particular in Alzheimer’s disease. Finally, we will give evidence of how the involvement of BDNF in the pathogenesis of brain glioblastoma has emerged, thus opening new avenues for the treatment of this deadly cancer.

show abstract

“…The anti-depressant activity of WY14643 appeared to involve activation of the brain derived neurotropic factor (BDNF) signaling cascade [44], a pathway implicated in a range of neuronal processes (depicted in Figure 1) [75][76][77][78]. It is well known that BDNF levels are found to be decreased in the hippocampus of depressed individuals and in animal models of this disorder [79][80][81][82]. Furthermore, the action of antidepressants, like fluoxetine, increase BDNF levels, which in turn correlates with an improvement of behavioral dysfunction [83].…”

Section: Mood Disordersmentioning

confidence: 99%

Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?

Tufano

Pinna

2020

Molecules

View full text Add to dashboard Cite

Recently, peroxisome proliferator-activated receptor (PPAR)-α and γ isoforms have been gaining consistent interest in neuropathology and treatment of neuropsychiatric disorders. Several studies have provided evidence that either the receptor expression or the levels of their endogenously-produced modulators are downregulated in several neurological and psychiatric disorders and in their respective animal models. Remarkably, administration of these endogenous or synthetic ligands improves mood and cognition, suggesting that PPARs may offer a significant pharmacological target to improve several neuropathologies. Furthermore, various neurological and psychiatric disorders reflect sustained levels of systemic inflammation. Hence, the strategy of targeting PPARs for their anti-inflammatory role to improve these disorders is attracting attention. Traditionally, classical antidepressants fail to be effective, specifically in patients with inflammation. Non-steroidal anti-inflammatory drugs exert potent antidepressant effects by acting along with PPARs, thereby strongly substantiating the involvement of these receptors in the mechanisms that lead to development of several neuropathologies. We reviewed running findings in support of a role for PPARs in the treatment of neurological diseases, including Alzheimer’s disease or psychiatric disorders, such as major depression. We discuss the opportunity of targeting PPARs as a future pharmacological approach to decrease neuropsychiatric symptoms at the same time that PPAR ligands resolve neuroinflammatory processes.

show abstract

Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment

Cited by 93 publications

References 144 publications

Comparison of serum protein profiles between major depressive disorder and bipolar disorder

Comparison of serum protein profiles between major depressive disorder and bipolar disorder

Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer

Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?

Contact Info

Product

Resources

About